替尔泊肽减少肥胖相关心衰患者的左室质量与心旁脂肪组织:SUMMIT CMR亚组研究
SUMMIT试验的CMR亚组纳入175例肥胖相关HFpEF患者,106例完成基线与52周MRI分析。替尔泊肽组经安慰剂校正后左室质量减少11g(95%CI:-19至-4g,P=0.004),心旁脂肪组织减少45mL(95%CI:-69至-22mL,P<0.001),左室质量变化与体重下降相关。
要点
- 替尔泊肽可显著降低肥胖相关HFpEF患者的左室质量和心旁脂肪组织。
- 左室质量下降与体重减轻相关,并与左室舒张末期容积及左房容积变化相关。
- 这些生理改变可能有助于解释主SUMMIT试验中心衰事件的减少。
核心结论
- 在肥胖相关HFpEF患者中,替尔泊肽治疗较安慰剂降低左室质量和心旁脂肪组织,左室质量变化与体重下降平行,可能贡献于主试验心衰事件的减少。
研究设计与样本
- SUMMIT试验的CMR亚组研究,175例肥胖相关HFpEF患者接受替尔泊肽(2.5mg皮下每周,增至最大15mg每周)或匹配安慰剂,基线和52周进行CMR多平面 cine 成像。
- 106例完成CMR且图像质量满足基线与52周左室、左房结构功能及心旁(心外膜+心包)脂肪组织分析,其中替尔泊肽组50例、安慰剂组56例。
主要发现
- 替尔泊肽组经安慰剂校正后左室质量减少11g(95%CI:-19至-4g,P=0.004)。
- 替尔泊肽组经安慰剂校正后心旁脂肪组织减少45mL(95%CI:-69至-22mL,P<0.001)。
- 左室质量变化与体重变化相关(P<0.02),与腰围和血压变化呈趋势相关(两者P=0.06)。
- 左室质量变化与左室舒张末期容积及左房舒张末期和收缩末期容积变化相关(均P<0.03)。
临床怎么用
- 对于肥胖相关HFpEF患者,替尔泊肽治疗可能通过减少左室质量和心旁脂肪组织带来结构性获益。
- 左室质量下降与体重减轻相关,提示减重是替尔泊肽心脏结构改善的重要关联因素。
局限性
- CMR亚组仅106例完成基线与52周分析,样本量有限。
- 左室质量变化与腰围和血压变化仅为趋势相关(P=0.06),未达统计学显著性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Obesity is a known risk factor for heart failure with preserved ejection fraction (HFpEF) and is considered a distinct phenotype with more concentric remodeling. Epicardial adipose tissue (EAT) is also increased in obesity-related HFpEF and is associated with adverse events. OBJECTIVES: The cardiac magnetic resonance (CMR) substudy of the SUMMIT trial aimed to examine the effects of tirzepatide on cardiac structure and function with the underlying hypothesis that it would reduce left ventricular (LV) mass and EAT in obesity-related HFpEF. METHODS: A total of 175 patients with obesity-related HFpEF from the parent study of tirzepatide (2.5 mg subcutaneously weekly, increasing to a maximum of 15 mg weekly) or matching placebo underwent CMR at baseline, which consisted of multiplanar cine imaging. A total of 106 patients completed the CMR and had adequate image quality for analysis of LV and left atrial structure and function and paracardiac (epicardial plus pericardial) adipose tissue at both baseline and 52 weeks. The prespecified primary endpoint of this substudy was between-group changes in LV mass. RESULTS: LV mass decreased by 11 g (95% CI: -19 to -4 g) in the treated group (n = 50) when corrected for placebo (n = 56) (P = 0.004). Paracardiac adipose tissue decreased in the treated group by 45 mL (95% CI: -69 to -22 mL) when corrected for placebo (P < 0.001). The change in LV mass in the treated group correlated with changes in body weight (P < 0.02) and tended to correlate with changes in waist circumference and blood pressure (P = 0.06 for both). The LV mass change also correlated with changes in LV end-diastolic volume and left atrial end-diastolic and end-systolic volumes (P < 0.03 for all). CONCLUSIONS: The CMR substudy of the SUMMIT trial demonstrated that tirzepatide therapy in obesity-related HFpEF led to reduced LV mass and paracardiac adipose tissue as compared with placebo, and the change in LV mass paralleled weight loss. These physiologic changes may contribute to the reduction in heart failure events seen in the main SUMMIT trial. (A Study of Tirzepatide [LY3298176] in Participants With Heart Failure With Preserved Ejection Fraction [HFpEF] and Obesity: The SUMMIT Trial; NCT04847557).
引用
- Kramer, Borlaug, Zile, et al. Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure: SUMMIT CMR Substudy. J Am Coll Cardiol. 2024. PMID: 39566869. doi:10.1016/j.jacc.2024.11.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。